RTRyuta Tanaka

Ryuta Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryuta Tanaka has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study

    by Yuichi Abe, Toshimitsu Hamasaki, Jun Natsume, Yukiko Mogami, Kei Murayama, Hideaki Shiraishi, Yuki Abe, Satoko Kumada, Ryuta Tanaka, Kenji Ihara, et al.

    An explorative study was conducted to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride combined with sodium ferrous citrate (SPP-004) in 10 pediatric patients with Leigh syndrome (LS) aged 3–24 months in 10 institutions between December 2014 and July 2019. The patients were randomized and allocated to the SPP-004 or placebo group for a 12-week double-blind period, followed by a 12-week open-label period with SPP-004 and then a long-term study of up to 180 weeks. The efficacy and safety were evaluated using the Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) and adverse events (AEs), respectively. No significant differences were found between groups in NPMDS scores, but prolonged SPP-004 treatment stabilized or improved scores. During the initial double-blind phase, the serum lactate levels increased in the placebo group but not in the SPP-004 group. Over the period of prolonged treatment with SPP-004, the average serum lactate level gradually decreased to a normal level. One patient died due to heart failure, presumably due to an underlying disease. Overall, 7 out of 10 patients received SPP-004 without developing severe AEs until the termination of the long-term study. Given the severe symptoms and poor prognosis of pediatric LS, NPMDS scores were indicative of stabilization in pediatric LS patients treated with SPP-004.


  • Nusinersen improved respiratory function in spinal muscular atrophy type 2

    by Ryuta Tanaka, Fujiko Fukushima, Keiichi Motoyama, Chie Kobayashi, Isho Izumi


  • Abnormal brain MRI signal in 18q-syndrome not due to dysmyelination

    by Ryuta Tanaka, Nobuaki Iwasaki, Masaharu Hayashi, Junko Nakayama, Tatsuyuki Ohto, Miho Takahashi, Tomokazu Numano, Kazuhiro Homma, Kenzo Hamano, Ryo Sumazaki


    • 1 November 2009
      • Vol. 41  (6) , 452-6

    [Two patients with congenital insensitivity to pain with anhidrosis showing marked prolongation of central conduction time in short latency somatosensory evoked potential].

    by Ryuta Tanaka, Kenji Sugai, Yoshinao Fujikawa, Hirofumi Komaki, Eiji Nakagawa, Yoshiaki Saito, Tatsuyuki Ohto, Toshiaki Hashimoto, Masayuki Sasaki

    We examined the evoked potentials in 2 patients, a 6-month-old girl and a 3-year-old boy, with congenital insensitivity to pain with anhidrosis (CIPA). While auditory brainstem response (ABR) in both patients showed normal latencies, flash visual evoked potential (FVEP) revealed delayed latency of wave IV (P100), and short latency somatosensory evoked potential (SSEP) demonstrated marked prolongation of the central conduction time (CCT; N13-N20 interval). The boy had West syndrome and his prolonged CCT might have been influenced by abnormal cortical activities. The girl did not have epilepsy and the abnormalities of her F-VEP and SSEP might have been caused by the developmental deficit of the central nervous system associated with the pathogenesis of CIPA.

    • 1 May 2007
      • Vol. 39  (3) , 202-5

    [Hiccup treated by administration of intranasal vinegar].

    by Nobuaki Iwasaki, Hideyo Kinugasa, Akimitsu Watanabe, Tomoko Katagiri, Ryuta Tanaka, Kenji Shin, Hideo Satoh

    A three-year old girl, who had severe cerebral palsy, severe mental retardation, and symptomatic epilepsy, was suffering from intractable hiccup that lasted for more than an hour since she was 2 years and 10 months old when she undertook tracheotomy and laryngotracheal separation. Sometimes this intractable hiccup was followed by respiratory arrest. Although the hiccup was resistant to conventional medications, the nose drops of small amount of vinegar showed a favorable effect on the hiccup. Intranasal vinegar might stimulate dorsal wall of nasopharynx where the pharyngeal branch of the glossopharyngeal nerve, which is thought as an afferent of the reflex arch of hiccup, is distributed. The administration of intranasal vinegar is a safe and handy method to stimulate dorsal wall of nasopharynx. We believe that intranasal vinegar administration could be a useful nonpharmacologic therapy to cease intractable hiccup.


    • 1 November 2003
      • Vol. 35  (6) , 511-4

    [A case of infantile epileptic apnea with congenital brain anomaly].

    by Tatsuyuki Ohto, Nobuaki Iwasaki, Miho Takahashi, Ryuta Tanaka, Kenzo Hamano, Akira Matsui

    Two months-old girl with psychomotor retardation had aminophylline-resistant apnea attacks and was investigated by video-EEG recording. She had hypogenesis of cerebral cortex and cerebellum and complete agenesis of corpus callosum. Left hemispheric 2 Hz rhythmic delta wave burst originating from the posterior temporal area lasted about 20 seconds, and was followed by an apnea attack persisting for 30 seconds. During the apnea attack, the basic activity of EEG was suppressed. The diagnosis of epileptic apnea was made, and the attacks were controlled with valproate sodium. Reports of cases of brain anomaly presenting with epileptic apnea are rare and this interesting case provided a clue to the pathomechanism of this condition.